Kinetically Guided Neoadjuvant Chemoradiotherapy Based on 5-Fluorouracil in Patients with Locally Advanced Rectal Cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F15%3A10315478" target="_blank" >RIV/00216208:11150/15:10315478 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00179906:_____/15:10315478

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s40262-014-0216-4" target="_blank" >http://dx.doi.org/10.1007/s40262-014-0216-4</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s40262-014-0216-4" target="_blank" >10.1007/s40262-014-0216-4</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Kinetically Guided Neoadjuvant Chemoradiotherapy Based on 5-Fluorouracil in Patients with Locally Advanced Rectal Cancer

Popis výsledku v původním jazyce

This study estimated patients' early response following neoadjuvant chemoradiotherapy (CHRT) of locally advanced rectal cancer based on 5-fluorouracil (5-FU). The target was to achieve pathological complete response and toxicities of grade LESS-THAN OR EQUAL TO2, using individual dosing predicted according to the steady-state plasma concentration (Css) and pharmacokinetic parameters of 5-FU: the area under the time-concentration curve at steady state (AUC) and clearance (CL). This open-label prospectivestudy enrolled 33 adult patients treated with 5-FU administered as a continuous intravenous infusion over 4-5 weeks, as follows: in Group 1a (N = 6), the patients received a standard dose of 300 mg/m2/24 h. In Group 1b (N = 7), the patients were treatedwith an escalated dose of 400-1,000 mg/m2/24 h. In Group 2 (N = 20), the patients were given dosing kinetically guided in order to reach the target range of 5-FU Css 50-100 ?g/L. Tolerability was tested according to Common Terminology Cr

Název v anglickém jazyce

Kinetically Guided Neoadjuvant Chemoradiotherapy Based on 5-Fluorouracil in Patients with Locally Advanced Rectal Cancer

Popis výsledku anglicky

This study estimated patients' early response following neoadjuvant chemoradiotherapy (CHRT) of locally advanced rectal cancer based on 5-fluorouracil (5-FU). The target was to achieve pathological complete response and toxicities of grade LESS-THAN OR EQUAL TO2, using individual dosing predicted according to the steady-state plasma concentration (Css) and pharmacokinetic parameters of 5-FU: the area under the time-concentration curve at steady state (AUC) and clearance (CL). This open-label prospectivestudy enrolled 33 adult patients treated with 5-FU administered as a continuous intravenous infusion over 4-5 weeks, as follows: in Group 1a (N = 6), the patients received a standard dose of 300 mg/m2/24 h. In Group 1b (N = 7), the patients were treatedwith an escalated dose of 400-1,000 mg/m2/24 h. In Group 2 (N = 20), the patients were given dosing kinetically guided in order to reach the target range of 5-FU Css 50-100 ?g/L. Tolerability was tested according to Common Terminology Cr

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NS9693" target="_blank" >NS9693: Individuální predikce dávkového režimu 5-fluorouracilu v léčbě kolorektálního karcinomu</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Pharmacokinetics

ISSN

0312-5963

e-ISSN

—

Svazek periodika

54

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

NZ - Nový Zéland

Počet stran výsledku

13

Strana od-do

503-515

Kód UT WoS článku

000355338600004

EID výsledku v databázi Scopus

2-s2.0-84939965747